Clinical trials
Retinal Vein Occlusion trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 3 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Unknown status | 13 |
| Terminated | 5 |
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Al-Azhar University | 2 |
| He Eye Hospital | 2 |
| Medical University of Vienna | 2 |
| Wills Eye | 2 |
| Assiut University | 1 |
| Barnes Retina Institute | 1 |
| Beijing Hospital | 1 |
| Benha University | 1 |
| Brian Burke, MPH | 1 |
| CHU de Reims | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Retinal Vein Occlusion | 50 |
| Macular Edema | 13 |
| Macular Degeneration | 11 |
| Diabetic Retinopathy | 10 |
| Glaucoma | 3 |
| Retinal Artery Occlusion | 3 |
| Choroidal Neovascularization | 2 |
| Ocular Hypertension | 2 |
| Cataract | 1 |
| Central Serous Chorioretinopathy | 1 |
Trials
Showing 26 to 50 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.